Cipla is currently trading at Rs. 595.50, up by 12.10 points or 2.07% from its previous closing of Rs. 583.40 on the BSE.
The scrip opened at Rs. 585.00 and has touched a high and low of Rs. 596.25 and Rs. 581.70 respectively. So far 108181 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 621.90 on 06-Feb-2017 and a 52 week low of Rs. 458.25 on 25-May-2016.
Last one week high and low of the scrip stood at Rs. 596.25 and Rs. 571.15 respectively. The current market cap of the company is Rs. 47705.17 crore.
The promoters holding in the company stood at 37.49%, while Institutions and Non-Institutions held 35.64% and 26.87% respectively.
Cipla has launched adult Hepatitis B vaccine in India. Under a co-exclusive agreement with Serum Institute of India (SII), the company will market the vaccine for adults while SII will market it for adults and children. The agreement will enable the company to provide affordable vaccines for a chronic disease like Hepatitis B. The company’s strong marketing network and reach will ensure maximum accessibility of the vaccines in India.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries.